keyword
MENU ▼
Read by QxMD icon Read
search

ramucirumab

keyword
https://www.readbyqxmd.com/read/29329598/treatment-outcome-of-anti-angiogenesis-through-vegf-pathway-in-the-management-of-gastric-cancer-a-systematic-review-of-phase-ii-and-iii-clinical-trials
#1
Brian Mawalla, Xianglin Yuan, Xiaoxiao Luo, Phillip L Chalya
OBJECTIVES: Advanced gastric cancer poses a therapeutic challenge worldwide. In randomised clinical trials, anti-VEGF has been reported as an essential agent for the treatment of advanced gastric cancer. This review aims at assessing the treatment outcome of anti-angiogenesis therapy through the VEGF pathway in the management of patients with advanced gastric cancer. RESULTS: During this review, 38 clinical trials were identified. Of these, 30 clinical trials were excluded, leaving eight trials of phase II and III...
January 12, 2018: BMC Research Notes
https://www.readbyqxmd.com/read/29327066/ramucirumab-induced-multiple-haemangiomas-of-the-skin-two-case-reports
#2
Hideyuki Kosumi, Wataru Nishie, Tatsuro Sugai, Ellen Toyonaga, Norihiro Yoshimoto, Hiroyuki Nakamura, Ryota Horibe, Yasuo Kitamura, Hiroshi Nakatsumi, Hiroshi Shimizu
No abstract text is available yet for this article.
December 20, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/29318901/ramucirumab-in-her-2-positive-gastroesophageal-adenocarcinoma-an-argument-for-overcoming-trastuzumab-resistance
#3
Mustapha Tehfe, Samer Tabchi, Maria Maddalena Laterza, Ferdinando De Vita
AIM: Patients with advanced gastric cancer have a relatively poor prognosis with few therapeutic alternatives beyond first-line therapy. The purpose of this manuscript is to highlight the potential for prolonged responses in patients with HER-2-positive disease. Patients, materials & methods: We analyzed the data of patients diagnosed with HER-2-positive-advanced gastric cancer who progressed on trastuzumab-based combination therapy and subsequently received second-line therapy consisting of ramucirumab in combination with paclitaxel...
January 10, 2018: Future Oncology
https://www.readbyqxmd.com/read/29318751/subgroup-analysis-of-east-asian-patients-in-regard-a-phase-iii-trial-of-ramucirumab-and-best-supportive-care-for-advanced-gastric-cancer
#4
Hyun Cheol Chung, Victor C Kok, Rebecca Cheng, Yanzhi Hsu, Mauro Orlando, Charles Fuchs, Jae Yong Cho
AIM: We describe a subgroup analysis assessing the efficacy and safety of ramucirumab monotherapy in East Asian (EA) patients from the REGARD trial. METHODS: Patients with advanced gastric or gastroesophageal junction adenocarcinoma with progressive disease were randomized 2:1 to receive ramucirumab (8 mg/kg) plus best supportive care (BSC) or placebo plus BSC every 2 weeks. Post hoc subset analyses were performed on the EA and non-EA intention-to-treat populations...
January 10, 2018: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29317191/randomized-double-blind-phase-ib-iii-study-of-erlotinib-with-ramucirumab-or-placebo-in-previously-untreated-egfr-mutant-metastatic-non-small-cell-lung-cancer-relay-phase-ib-results
#5
Martin Reck, Edward B Garon, Luis Paz-Ares, Santiago Ponce, Jesus Corral Jaime, Oscar Juan, Ernest Nadal, Katsuyuki Kiura, Ryan C Widau, Shuang He, Rita Dalal, Pablo Lee, Kazuhiko Nakagawa
BACKGROUND: Despite the likelihood of an initial response to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non-small-cell lung cancer (NSCLC) patients develop disease progression. Antiangiogenic agents in combination with an EGFR TKI might provide additional benefit in patients with EGFR-mutant NSCLC. In this article we report safety, exposure, and progression-free survival (PFS) results for part A (phase Ib) of RELAY, a randomized, double-blind, phase Ib/III study investigating safety and efficacy of erlotinib (EGFR TKI) with ramucirumab (anti-vascular endothelial growth factor receptor-2 antibody) or placebo in first-line EGFR-mutant stage IV NSCLC...
November 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29277168/subclinical-thiamine-deficiency-in-patients-with-abdominal-cancer
#6
Hideki Onishi, Mayumi Ishida, Iori Tanahashi, Takao Takahashi, Yoshitada Taji, Kenji Ikebuchi, Daisuke Furuya, Tatsuo Akechi
OBJECTIVE: Thiamine is an essential coenzyme for oxidative metabolisms; however, it is not synthesized in the human body, and the average thiamine storage capacity is approximately 18 days. Therefore, thiamine deficiency (TD) can occur in any condition of unbalanced nutrition. If TD is left untreated, it causes the neuropsychiatric disorder Wernicke encephalopathy (WE). Although WE is a medical emergency, it is sometimes overlooked because most patients with WE do not exhibit all of the typical symptoms, including delirium, ataxia, and ophthalmoplegia...
December 26, 2017: Palliative & Supportive Care
https://www.readbyqxmd.com/read/29260338/a-case-of-ramucirumab-related-gastrointestinal-perforation-in-gastric-cancer-with-small-bowel-metastasis
#7
Shinya Urakawa, Daisuke Sakai, Yasuhiro Miyazaki, Toshihiro Kudo, Aya Katou, Chiaki Inagaki, Koji Tanaka, Tomoki Makino, Tsuyoshi Takahashi, Yukinori Kurokawa, Makoto Yamasaki, Kiyokazu Nakajima, Shuji Takiguchi, Taroh Satoh, Masaki Mori, Yuichiro Doki
BACKGROUND: Ramucirumab is a monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR-2). Ramucirumab either alone or in combination with paclitaxel (PTX) has been found to be safe and effective for patients with previously treated advanced gastric cancer. One of the serious adverse events associated with ramucirumab is gastrointestinal (GI) perforation. CASE PRESENTATION: We report the case of a 67-year-old man who developed a ramucirumab-related GI perforation while undergoing treatment for gastric cancer with small bowel metastasis...
December 19, 2017: Surgical Case Reports
https://www.readbyqxmd.com/read/29250745/effective-treatment-of-cytotoxic-agent-refractory-alpha-fetoprotein-producing-gastric-cancer-with-ramucirumab-a-case-report-and-review-of-the-literature
#8
Jun Takada, Hiroshi Araki, Noritaka Ozawa, Tomohiko Sugiyama, Masaya Kubota, Takashi Ibuka, Masahito Shimizu
No abstract text is available yet for this article.
December 18, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/29231057/a-critical-review-on-ramucirumab-in-the-treatment-of-advanced-urothelial-cancer
#9
Panagiotis J Vlachostergios, Aileen Lee, Charlene Thomas, Ryan Walsh, Scott T Tagawa
Advanced urothelial cancer (UC) is a lethal disease despite current advances in systemic therapy, including platinum chemotherapy combinations and immune checkpoint inhibition. Tumor angiogenesis is involved in UC growth and metastatic progression. Proangiogenic signaling through the VEGFR is a key process in UC with prognostic significance. Targeting of VEGFR2 with the monoclonal antibody ramucirumab has been tested in various different tumor types. In this review, we discuss the development of the drug in the context of its preclinical and clinical use with a focus on UC...
December 12, 2017: Future Oncology
https://www.readbyqxmd.com/read/29228087/analysis-of-angiogenesis-biomarkers-for-ramucirumab-efficacy-in-patients-with-metastatic-colorectal-cancer-from-raise-a-global-randomized-double-blind-phase-iii-study
#10
J Tabernero, R R Hozak, T Yoshino, A L Cohn, R Obermannova, G Bodoky, R Garcia-Carbonero, T-E Ciuleanu, D C Portnoy, J Prausová, K Muro, R W Siegel, R J Konrad, H Ouyang, S A Melemed, D Ferry, F Nasroulah, E Van Cutsem
Background: The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo+FOLFIRI as second-line metastatic colorectal cancer (mCRC) treatment. To identify patients who benefit the most from VEGFR-2 blockade, the RAISE trial design included a prospective and comprehensive biomarker program that assessed the association of biomarkers with ramucirumab efficacy outcomes...
December 7, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29209523/second-line-treatments-moving-towards-an-opportunity-to-improve-survival-in-advanced-gastric-cancer
#11
REVIEW
Massimiliano Salati, Katia Di Emidio, Vittoria Tarantino, Stefano Cascinu
Gastric cancer is the third leading cause of cancer-related death globally with approximately 723 000 deaths every year. Most patients present with advanced unresectable or metastatic disease, only amenable to palliative systemic treatment and a median survival uncommonly exceeding 12 months. Over the last years, the efficacy of chemotherapy combination has plateaued and the introduction of the anti-human epidermal growth factor receptor 2 trastuzumab has resulted in a limited survival gain in the upfront setting...
2017: ESMO Open
https://www.readbyqxmd.com/read/29195550/a-three-time-point-method-for-assessing-kinetic-parameters-of-64cu-labeled-ramucirumab-trapping-in-vegfr-2-positive-lung-tumors
#12
Eric Laffon, Roger Marthan
OBJECTIVE: To describe a three-time-point method for estimating kinetic parameters involved in 64Cu-labeled Ramucirumab (64Cu-NOTA-RamAb) trapping of VEGFR-2 positive lung tumors. MATERIALS AND METHODS: Positron emission tomography (microPET) data of tumor-bearing mice for 64Cu-NOTA-RamAb trapping in VEGFR-2 positive HCC4006 tumor were used, involving tissue activity measurements acquired at 3, 24 and 48 h post-injection, without and with administration of RamAb blocking dose...
November 2017: Physica Medica: PM
https://www.readbyqxmd.com/read/29191593/outcomes-in-patients-with-aggressive-or-refractory-disease-from-revel-a-randomized-phase-iii-study-of-docetaxel-with-ramucirumab-or-placebo-for-second-line-treatment-of-stage-iv-non-small-cell-lung-cancer
#13
Martin Reck, Luis Paz-Ares, Paolo Bidoli, Federico Cappuzzo, Shaker Dakhil, Denis Moro-Sibilot, Hossein Borghaei, Melissa Johnson, Robert Jotte, Nathan A Pennell, Frances A Shepherd, Anne Tsao, Michael Thomas, Gebra Cuyun Carter, Faye Chan-Diehl, Ekaterine Alexandris, Pablo Lee, Annamaria Zimmermann, Andreas Sashegyi, Maurice Pérol
OBJECTIVES: The REVEL study demonstrated improved efficacy for patients with advanced non-small cell lung cancer treated with ramucirumab plus docetaxel, independent of histology. This exploratory analysis characterized the treatment effect in REVEL patients who were refractory to prior first-line treatment. MATERIALS AND METHODS: Refractory patients had a best response of progressive disease to first-line treatment. Endpoints included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), quality of life (QoL), and safety...
October 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29191585/treatment-outcomes-by-histology-in-revel-a-randomized-phase-iii-trial-of-ramucirumab-plus-docetaxel-for-advanced-non-small-cell-lung-cancer
#14
Luis G Paz-Ares, Maurice Pérol, Tudor-Eliade Ciuleanu, Ruben Dario Kowalyszyn, Martin Reck, Conrad R Lewanski, Konstantinos Syrigos, Oscar Arrieta, Kumar Prabhash, Keunchil Park, Joanna Pikiel, Tuncay Göksel, Pablo Lee, Anna Zimmermann, Gebra Cuyun Carter, Ekaterine Alexandris, Edward B Garon
OBJECTIVES: Ramucirumab, a recombinant human immunoglobulin G1 monoclonal antibody inhibiting vascular endothelial growth factor receptor-2, increased overall survival (OS) combined with docetaxel versus docetaxel alone in non-small cell lung cancer (NSCLC) in the REVEL trial. Pre-specified exploratory analysis examined efficacy and safety by histology. MATERIALS AND METHODS: 1253 patients with NSCLC were randomized to receive ramucirumab (10mg/kg; n=628) plus docetaxel (75mg/m2) or placebo plus docetaxel (n=625) after disease progression on or after platinum-based therapy, with or without bevacizumab or maintenance therapy...
October 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29188737/eruptive-cherry-angiomas-developing-in-a-patient-treated-with-ramucirumab
#15
Pablo Espinosa Lara, Camino Medina-Puente, Alejandro Riquelme Oliveira, José Jiménez-Reyes
No abstract text is available yet for this article.
November 30, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29182797/palliative-chemotherapy-and-targeted-therapies-for-esophageal-and-gastroesophageal-junction-cancer
#16
REVIEW
Vincent T Janmaat, Ewout W Steyerberg, Ate van der Gaast, Ron Hj Mathijssen, Marco J Bruno, Maikel P Peppelenbosch, Ernst J Kuipers, Manon Cw Spaander
BACKGROUND: Almost half of people with esophageal or gastroesophageal junction cancer have metastatic disease at the time of diagnosis. Chemotherapy and targeted therapies are increasingly used with a palliative intent to control tumor growth, improve quality of life, and prolong survival. To date, and with the exception of ramucirumab, evidence for the efficacy of palliative treatments for esophageal and gastroesophageal cancer is lacking. OBJECTIVES: To assess the effects of cytostatic or targeted therapy for treating esophageal or gastroesophageal junction cancer with palliative intent...
November 28, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29175097/cost-effectiveness-of-paclitaxel-ramucirumab-combination-therapy-for-advanced-gastric-cancer-progressing-after-first-line-chemotherapy-in-japan
#17
Shota Saito, Yusuke Muneoka, Takashi Ishikawa, Kouhei Akazawa
PURPOSE: The combination of paclitaxel + ramucirumab is a standard second-line treatment in patients with advanced gastric cancer. This therapy has been associated with increased median overall survival and progression-free survival compared with those with paclitaxel monotherapy. We evaluated the cost-effectiveness of paclitaxel + ramucirumab combination therapy in patients with advanced gastric cancer, from the perspective of health care payers in Japan. METHODS: We constructed a Markov model to compare, over a time horizon of 3 years, the costs and effectiveness of the combination of paclitaxel + ramucirumab and paclitaxel alone as second-line therapies for advanced gastric cancer in Japan...
November 23, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29151542/ramucirumab-plus-paclitaxel-a-possible-new-chemotherapy-regimen-for-neuroendocrine-carcinoma-of-the-stomach
#18
Yoshiharu Motoo
No abstract text is available yet for this article.
November 20, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29151523/neuroendocrine-carcinoma-of-the-stomach-a-response-to-combination-chemotherapy-consisting-of-ramucirumab-plus-paclitaxel
#19
Yuki Matsubara, Takayuki Ando, Ayumu Hosokawa, Hiroshi Mihara, Hiroaki Takagi, Naokatsu Nakata, Hiroki Yoshita, Sohachi Nanjo, Shinya Kajiura, Haruka Fujinami, Toshiro Sugiyama
Extrapulmonary neuroendocrine carcinoma (NEC) is a rare disease, and there is no standard chemotherapy. A 73-year-old man was diagnosed with advanced gastric NEC. He received chemotherapy of irinotecan plus cisplatin, and amrubicin monotherapy. After failure of second-line chemotherapy, he received ramucirumab plus paclitaxel; this treatment was chosen because vascular endothelial growth factor 2 was strongly expressed in the tumor endothelial cells. After two cycles, his NEC had markedly reduced in size, and he continued with this treatment for over eight months...
November 20, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29138380/-three-patients-with-gastric-cancer-who-underwent-surgery-during-ramucirumab-treatment
#20
Hayato Omori, Sadayuki Kawai, Rie Makuuchi, Tomoyuki Irino, Masanori Tokunaga, Yutaka Tanizawa, Etsuro Bando, Taiichi Kawamura, Hirofumi Yasui, Masanori Terashima
According to the REGARD and RAINBOW trials, ramucirumab(RAM)was introduced as second-line therapy for advanced or metastatic gastric cancer. RAM may impair wound healing due to the inhibition of angiogenesis; details on the postoperative course of patients who underwent surgery during RAM treatment remain unclear. Between 2011 and 2016, 93 patients with incurable gastric cancer were treated with RAM in our institute. Among them, 3 patients underwent surgery after RAM treatment. Case 1: A 74-year-old man with liver metastasis from gastric cancer was treated with a paclitaxel(PTX)plus RAM regimen...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
46644
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"